Concepts (59)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.58 | Why? |
| Mobile Health Units | 1 | 2021 | 741 | 0.53 | Why? |
| Skilled Nursing Facilities | 1 | 2021 | 1098 | 0.46 | Why? |
| Central Nervous System Sensitization | 1 | 2021 | 20 | 0.23 | Why? |
| Drug Combinations | 2 | 2021 | 3852 | 0.22 | Why? |
| Home Infusion Therapy | 1 | 2021 | 128 | 0.20 | Why? |
| Minnesota | 1 | 2021 | 509 | 0.19 | Why? |
| Administration, Intravenous | 1 | 2021 | 1115 | 0.17 | Why? |
| Multimorbidity | 1 | 2021 | 703 | 0.16 | Why? |
| Disease-Free Survival | 1 | 2021 | 1654 | 0.16 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.14 | Why? |
| Patients | 1 | 2021 | 1167 | 0.12 | Why? |
| Critical Pathways | 1 | 2021 | 1587 | 0.10 | Why? |
| Fatigue | 1 | 2021 | 2479 | 0.10 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.10 | Why? |
| Health Status | 1 | 2021 | 3259 | 0.08 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.08 | Why? |
| Remote Consultation | 1 | 2020 | 2396 | 0.07 | Why? |
| Antibodies, Monoclonal | 2 | 2021 | 8041 | 0.07 | Why? |
| Referral and Consultation | 1 | 2021 | 4816 | 0.07 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.06 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.06 | Why? |
| Female | 5 | 2021 | 380317 | 0.05 | Why? |
| Aged | 3 | 2021 | 215776 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Quality of Life | 1 | 2021 | 9820 | 0.05 | Why? |
| Humans | 10 | 2021 | 930598 | 0.05 | Why? |
| Middle Aged | 3 | 2021 | 270681 | 0.05 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.04 | Why? |
| Organizational Culture | 1 | 2021 | 395 | 0.04 | Why? |
| Male | 4 | 2021 | 367725 | 0.04 | Why? |
| Efficiency, Organizational | 1 | 2021 | 482 | 0.04 | Why? |
| Adult | 4 | 2021 | 244371 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.04 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.03 | Why? |
| Program Development | 1 | 2021 | 1089 | 0.03 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.03 | Why? |
| Intersectoral Collaboration | 1 | 2021 | 1065 | 0.03 | Why? |
| Informed Consent | 1 | 2021 | 890 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.03 | Why? |
| Neoplasms | 1 | 2021 | 17251 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.03 | Why? |
| Aged, 80 and over | 1 | 2021 | 88759 | 0.03 | Why? |
| Young Adult | 1 | 2021 | 93724 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Monitoring, Physiologic | 1 | 2021 | 1956 | 0.03 | Why? |
| Clinical Protocols | 1 | 2021 | 2734 | 0.02 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.02 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.02 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| United States | 1 | 2021 | 46150 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |